drugset
drugset / Trial / NCT03899298

Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions

NCT03899298 ↗

Phase 1 Not yet recruiting 5000 enrolled R3 Stem Cell
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To determine the safety and efficacy of Amniotic and Umbilical Cord Tissue for the treatment of the following condition categories: Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions. The hypotheses are that the treatments are not only extremely safe, but also statistically beneficial for all conditions. Outcomes will be determined by numerous valid outcome instruments that compile general quality of life information along with condition-specific information as well.

Timeline

Start
2019-09-01
Primary completion
2024-03-20
Completion
2029-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Amniotic and Umbilical Cord Tissue Procedure Cell therapy — Intravenous

Indications

Alzheimer disease arthritic joint disease autoimmune disease cardiomyopathy chronic obstructive pulmonary disease congestive heart failure erectile dysfunction impaired renal function disease kidney failure peripheral neuropathy stroke disorder